Молекулярно-генетические и цитогенетические характеристики спорадического рака почки: обзор литературы

Источниками для данного обзора литературы послужили не менее 100 публикаций, посвященных генетическим основам патогенеза светлоклеточного, папиллярного и хромофобного спорадического рака почки, в которых рассматривалась роль соматических генных и хромосомных мутаций в инициации, промоции и опухолевой прогрессии спорадического почечно-клеточного рака и подчеркивалась значимость определения мутагенного профиля почечно-клеточного рака для прогноза для пациентов.

1. Состояние онкологической помощи населению России в 2019 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2020. 239 с.

2. Михайленко Д.С. Анализ молекулярно-генетических нарушений, ассоциированных с развитием злокачественных новообразований почки. Дис. … канд. мед. наук. М., 2008. 123 с.

3. Брага Э.А., Жинжило Т.А., Колпаков А.В. и др. Профили экспрессии и метилирования генов при светлоклеточной карциноме почки. Альманах клинической медицины 2016;44(5):546–57. DOI: 10.18786/2072-05052016-44-5-546-557

4. Chow W.H., Dong L.M., Devesa S.S. Epidemiology and risk factors for kidney cancer. Nat Rev Urol 2010;7(5):245–57. DOI: 10.1038/nrurol.2010.46

5. Welch H.G., Black W.C. Overdiagnosis in cancer. J Nat Cancer Inst 2010;102(9):605–13. DOI: 10.1093/jnci/djq099

6. Li P., Znaor A., Holcatova I. et al. Regional geographic variations in kidney cancer incidence rates in European countries. Eur Urol 2015;67(6):1134–41. DOI: 10.1016/j.eururo.2014.11.001

7. Choueiri T.K., Fay A.P., Gagnon R. et al. The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma. Clin Cancer Res 2013;19(18):5218–26. DOI: 10.1158/1078-0432.CCR-13-0491

8. Audenet F., Yates D.R., Cancel-Tassin G. et al. Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine. BJU Int 2012;109(12): 1864–70. DOI: 10.1111/j.1464-410X.2011.10661.x

9. Bader H.L., Hsu T. Systemic VHL gene functions and the VHL disease. FEBS Lett 2012;586(11):1562–9. DOI: 10.1016/j.febslet.2012.04.032

10. Портниченко В.И., Носарь В.И., Портниченко А.Г. и др. Фазовые изменения энергетического метаболизма. Фізіол журн 2012;58(4):3–20. DOI: 10.15407/fz58.04.003

11. Semenza G.L. Regulation of oxygen homeostasis by hypoxia-inducible factor 1. Physiology (Bethesda) 2009;24:97–106. DOI: 10.1152/physiol.00045.2008

12. Myllyharju J., Koivunen P. Hypoxia-inducible factor prolyl 4-hydroxylases: common and specific roles. Biol Chem 2013;394(4):435–48. DOI: 10.1515/hsz-2012-0328

13. Павлов А.Д., Морщакова Е.Ф., Румянцев А.Г. Эритропоэз, эритропоэтин, железо. Молекулярные и клинические аспекты. М.: ГЭОТАР-Медиа, 2011. 299 с.

14. Zagorska A., Dulak J. HIF-1: knowns and unknowns of hypoxia sensing. Acta Biochimica Polonica 2004;51(3):563–85.

15. Qingdong K., Costa M. Hypoxia-inducible factor-1. Mol Pharmacol 2006;70(5):1469–80. DOI: 10.1124/mol.106.027029

16. Sendoel A., Kohler I., Fellmann C. et al. HIF-1 antagonizes p53mediated apoptosis through a secreted neuronal tyrosinase. Nature 2010;465(7298):577–83. DOI: 10.1038/nature09141

17. Rechsteiner M.P., von Teichman A., Nowicka A. et al. VHL gene mutations and their effects on hypoxia inducible factor HIF-α: identification of potential driver and passenger mutations. Cancer Res 2011;71(16):5500–11. DOI: 10.1158/0008-5472.CAN-11-0757

18. Arjumand W., Sultana S. Role of the VHL gene mutation in human renal cell carcinoma. Tumor Biol 2012 33(1):9–16. DOI: 10.1007/s13277-011-0257-3

19. Шейнов А.А., Татарский В.В., Азиева А.М. и др. Функции изоформ PHF10 субъединицы PBAF комплекса, ремоделирующего хроматин. Вавиловский журнал генетики и селекции 2019; 23(2):184–9. DOI: 10.18699/VJ19.480

20. Clapier C.R., Cairns B.R. The biology of chromatin remodeling complexes. Annu Rev Biochem 2009;78:273–304. DOI: 10.1146/annurev.biochem.77.062706.153223

21. Thompson M. Polybromo-1: the chromatin targeting subunit of the PBAF complex. Biochimie 2009;91(3):309–19. DOI: 10.1016/j.biochi.2008.10.019

22. Roy D.M., Walsh L.A., Chan T.A. Driver mutations of cancer epigenomes. Protein Cell 2014;5(4):265–96. DOI: 10.1007/s13238-014-0031-6

23. Brownlee P.M., Chambers A.L., Oliver A.W., Downs J.A. Cancer and the bromodomains of BAF180. Biochem Soc Trans 2012;40(2):364–9. DOI: 10.1042/BST20110754

24. Nam S.J., Lee C., Park J.H., Moon K.C. Decreased PBRM1 expression redicts unfavorable prognosis in patients with clear cell renal cell carcinoma. Urol Oncol 2015;33(8):340e9–16. DOI: 10.1016/j.urolonc.2015.01.010

25. Keefe S.M., Nathanson K.L., Rathmell W.K. The molecular biology of renal cell carcinoma. Semin Oncol 2013;40(4):421–8. DOI: 10.1053/j.seminoncol.2013.05.006

26. Задворнов А.А., Голомидов А.В., Григорьев Е.В. Биомаркеры перинатального поражения центральной нервной системы. Неонатология: новости, мнения, обучение 2017;(1):47–57. DOI: 10.24411/2308-2402-2017-00016

27. Komander D. The emerging complexity of protein ubiquitination. J Biochem Soc Trans 2009;37(5):937–53. DOI: 10.1042/BST0370937

28. Kimura Y., Tanaka K. Regulatory mechanisms involved in the control of ubiquitin homeostasis. J Biochem 2010;147(6):793–8. DOI: 10.1093/jb/mvq044

29. Amaro А. The biology of uveal melanoma. Cancer and Metastasis Rev 2017;36(1):109–40. DOI: 10.1007/s10555-017-9663-3

30. Немцова М.В., Михайленко Д.С., Морозов А.А. и др. Молекулярно-генетические исследования спорадических опухолей почки. Вестник Тамбовского государственного университета 2017;22(6):1405–15.

31. Li F., Mao G., Tong D. et al. The mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutS-α. Cell 2013;153(3):590–600. DOI: 10.1016/j.cell.2013.03.025

32. Carvalho S., Vítor A.C., Sridhara S.C. et al. SETD2 is required for DNA double-strand break repair and activation of the p53-mediated checkpoint. Elife 2014;3:e02482. DOI: 10.7554/eLife.02482

33. Спивак И.М. Экология. Повреждение и репарация ДНК: учебное пособие. СПб.: Издательство политехнического университета, 2006. DOI: 10.18720/SPBPU/2/si20-713

34. Kanu N., Grönroos E., Martinez P. et al. SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair. Oncogene 2015;34(46):5699–708. DOI: 10.1038/onc.2015.24

35. Stone L. SETD2 affects DNA replication. Nat Rev Urol 2015;12(4):183. DOI: 10.1038/nrurol.2015.53

36. Giaccia A.J. A new chromatin-cytoskeleton link in cancer. Mol Cancer Res 2016;14(12):1173–5. DOI: 10.1158/1541-7786.MCR-16-0250

37. Hacker K.E., Fahey C.C., Shinsky S.A. et al. Structure/function analysis of recurrent mutations in SETD2 protein reveals a critical and conserved role for a SET domain residue in maintaining protein stability and histone H3 Lys-36 trimethylation. J Biol Chem 2016; 291(40):21283–95. DOI: 10.1074/jbc.M116.739375

38. Fahey C.C., Davis I.J. SETting the stage for cancer development: SETD2 and the consequences of lost methylation. Cold Spring Harb Perspect Med 2017;7(5):a026468. DOI: 10.1101/cshperspect. a026468

39. Dronamraju R., Jha D.K., Eser U. et al. Set2 methyltransferase facilitates cell cycle progression by maintaining transcriptional fidelity. Nucleic Acids Res 2018;46(3):1331–44. DOI: 10.1093/nar/gkx1276

40. Li J., Ahn J.H., Wang G.G. et al. Understanding histone H3 lysine 36 methylation and its deregulation in disease. Cell Mol Life Sci 2019;76(15):2899–916. DOI: 10.1007/s00018-019-03144-y

41. Hakimi A.A., Ostrovnaya I., Reva B. et al. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP-1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin Cancer Res 2013;19(12):3259–67. DOI: 10.1158/1078-0432.CCR-12-3886

42. Papadimitrakopoulou V., Adjei A.A. The Akt/mTOR and mitogenactivated protein kinase pathways in lung cancer therapy. J Thorac Oncol 2006;1(7):749–51.

43. Engelman J.A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009;9(8):550–62. DOI: 10.1038/nrc2664

44. Bader A.G., Kang S., Zhao L., Vogt P.K. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 2005;5(12):921–9. DOI: 10.1038/nrc1753

45. Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005;307(5712):1098–101. DOI: 10.1126/science.1106148

46. Shaw R.J., Bardeesy N., Manning B.D. et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 2004;6(1):91–9. DOI: 10.1016/j.ccr.2004.06.007

47. Murphy M., Brown G., Wallin C. et al. Gene Help: Integrated Access to Genes of Genomes in the Reference Sequence Collection. Bethesda (MD): National Center for Biotechnology Information (US), 2005 (Last Updated: August 15, 2019). 69 p.

48. Keniry M., Parsons R. The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene 2008;27(41):5477–85. DOI: 10.1038/onc.2008.248

49. Gao T., Furnari F., Newton A.C. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell 2005;18(1):13–24. DOI: 10.1016/j.molcel.2005.03.008

50. Shaw R.J., Cantley L.C. Ras, PI(3):K and mTOR signaling controls tumour cell growth. Nature 2006;441(7092):424–30. DOI: 10.1038/nature04869

51. Sofer A., Lei K., Johannessen C.M. Regulation of mTOR and cell growth in response to energy stress by REDD1. Mol Cell Biol 2005;25(14):5834–45. DOI: 10.1128/MCB.25.14.5834-5845.2005

52. Reutor V.E., Presti J.C.Jr. Contemporary approach to the classification of renal epithelial tumors. Semin Oncol 2000;27(2):124–37.

53. Ku J.H., Moon K.C., Kwak C. et al. Is there a role of the histologic subtypes of papillary renal cell carcinoma as a prognostic factor? Jpn J Clin Oncol 2009;39(10):664–70. DOI: 10.1093/jjco/hyp075

54. Courthod G., Tucci M., Di Maio M., Scaqliotti G.V. Papillary renal cell carcinoma: a review of the current therapeutic landscape. Crit Rev Oncol Hematol 2015;96(1):100–12. DOI: 10.1016/j.critrevonc.2015.05.008

55. Wang K., Yuen S.T., Xu J. et al. Whole-genome sequencing and com-prehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet 2014;46(6):573–82. DOI: 10.1038/ng.2983

56. Garcia-Guzman M., Dolfi F., Zeh K., Vuori K. Met-induced JNK activation is mediated by the adapter protein Crk and correlates with the Gab1-Crk signaling complex formation. Oncogene 1999;18(54):7775–86. DOI: 10.1038/sj.onc.1203198

57. Paumelle R., Tulasne D., Kherrouche Z. et al. Hepatocyte growth factor/scatter factor activates the ETS1 transcription factorby a RAS-RAF-MEK-ERK signaling pathway. Oncogene 2002;21(15):2309–19. DOI: 10.1038/sj.onc.1205297

58. Syed Z.A., Yin W., Hughes K. et al. HGF/c-met/Stat3 signaling during skin tumor cell invasion: indications for a positive feedback loop. BMC Cancer 2011;11:180. DOI: 10.1186/1471-2407-11-180

59. Kang X.L., Zou H., Pang L.J. et al. Chromosomal imbalances revealed in primary renal cell carcinomas by comparative genomic hybridization. Int J Clin Exp Pathol 2015;8(4):3636–47.

60. Linehan W.M., Spellman P.T., Ricketts C.J. et al. Comprehensive molecular characterization of papillary renal-cell carcinoma. Cancer Genome Atlas Research Network. N Engl J Med 2016;374(2):135–45. DOI: 10.1056/NEJMoa1505917

61. Zhao R., Choi B.Y., Lee M.H. et al. Implications of genetic and epigenetic alterations of CDKN2A(p16(INK4a)) in cancer. EBioMedicine 2016;8:30–9. DOI: 10.1016/j.ebiom.2016.04.017

62. Kuiper R.P., Schepens M., Thijssen J. et al. Regulation of the MiTF/ TFE bHLH LZ transcription factors through restricted spatial express ion and alternative splicing of functional domains. Nucleic Acids Res 2004;32(8):2315–22. DOI: 10.1093/nar/gkh571

63. Liu R., Peng J., Wang H. et al. Oxysophocarpine retards the growth and metastasis of oral squamous cell carcinoma by targeting the Nrf2/HO-1 axis. Cell Physiol Biochem 2018;49(5):1717–33. DOI: 10.1159/000493615

64. Ткачев В.О., Меньщикова Е.Б., Зенков Н.К. Механизм работы сигнальной системы Nrf2/Keap1/ARE. Биохимия 2011;76(4):502–19.

65. Chapple S.J., Siow R.C., Mann G.E. Crosstalk between Nrf2 and the proteasome: therapeutic potential of Nrf2 inducers in vascular disease and aging. Int J Biochem Cell Biol 2012;44(8):1315–20. DOI: 10.1016/j.biocel.2012.04.021

66. Hybertson B.M., Gao B., Bose S.K., McCord J.M. Oxidative stress in health and disease: the therapeutic potential of Nrf2 activation. Mol Aspects Med 2011;32(4–6):234–46. DOI: 10.1016/j.mam.2011.10.006

67. Pandey P., Singh A.K., Singh M. et al. The see-saw of Keap1-Nrf2 pathway in cancer. Crit Rev Oncol Hematol 2017;116:89–98. DOI: 10.1016/j.critrevonc.2017.02.006

68. Зенков Н.К., Кожин П.М., Вчерашняя А.В. и др. Особенности редокс-регуляции в опухолевых клетках. Сибирский научный медицинский журнал 2019;39(2):17–26. DOI: 10.15372/SSMJ20190202

69. Турпаев К.Т. Сигнальная система Nrf2-Keap1. Механизм регуляции и значение для защиты клеток от токсического действия ксенобиотиков и электрофильных соединений. Биохимия 2013;78(2):147–66.

70. Jeddi F., Soozangar N., Sadeghi M.R. et al. Contradictory roles of Nrf2/Keap1 signaling pathway in cancer prevention/promotion and chemoresistance. DNA Repair 2017;54:13–21. DOI: 10.1016/j.dnarep.2017.03.008

71. Kim J., Keum Y.S. NRF2, a key regulator of antioxidants with two faces towards cancer. Oxid Med Cell Longev 2016;2016:276457. DOI: 10.1155/2016/2746457

72. Menegon S., Columbano A., Giordano S. The dual roles of NRF2 in cancer. Trends Mol Med 2016;22(7):578–93. DOI: 10.1016/j.molmed.2016.05.002

73. Jaramillo M.C., Zhang D.D. The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev 2013;27(20):2179–91. DOI: 10.1101/gad.225680.113

74. Suzuki T., Motohashi H., Yamamoto M. Toward clinical application of the Keap1-Nrf2 pathway. Trends Pharm Sci 2013;34(6):340–6. DOI: 10.1016/j.tips.2013.04.005

75. Basak P., Sadhukhan P., Sarkar P., Sil P.C. Perspectives of the Nrf-2 signaling pathway in cancer progression and therapy. Toxicol Rep 2017;4:306–18. DOI: 10.1016/j.toxrep.2017.06.002

76. Ngo H.K.C., Kim D.H., Cha Y.N. et al. Nrf2 mutagenic activation drives hepatocarcinogenesis. Cancer Res 2017;77(18):4797–808. DOI: 10.1158/0008-5472.CAN-16-3538

77. Li C., Cheng L., Wu H. et al. Activation of the KEAP1-NRF2-ARE signaling pathway reduces oxidative stress in Hep2 cells. Mol Med Rep 2018;18(3):2541–50. DOI: 10.3892/mmr.2018.9288

78. Raghunath A., Sundarraj K., Arfuso F. et al. Dysregulation of Nrf2 in hepatocellular carcinoma: role in cancer progression and chemo- resistance. Cancers 2018;10(12):481. DOI: 10.3390/cancers10120481

79. Shibata T., Ohta T., Tong K.I. et al. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc Natl Acad Sci USA 2008;105(36):13568–73. DOI: 10.1073/pnas.0806268105

80. Adam J., Hatipoglu E., O’Flaherty L. et al. Renal cyst formation in Fh1-deficient mice is independent of the HIF/PHD pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell 2011;20(4):524–37. DOI: 10.1016/j.ccr.2011.09.006

81. Hu Y., Ju Y., Lin D. et al. Mutation of the Nrf2 gene in non-small cell lung cancer. Mol Biol Rep 2012;39(4):4743–7. DOI: 10.1007/s11033-011-1266-4

82. Ooi A., Dykema K., Ansari A. et al. CUL3 and NRF2 mutations confer an NRF2 activation phenotype in a sporadic form of papillary renal cell carcinoma. Cancer Res 2013;73(7):2044–51. DOI: 10.1158/0008-5472.CAN-12-3227

83. Best S.A., Sutherland K.D. “Keaping” a lid on lung cancer: the Keap1-Nrf2 pathway. Cell Cycle 2018;17(14):1696–707. DOI: 10.1080/15384101.2018.1496756

84. Kerins M.J., Ooi A. A catalogue of somatic NRF2 gain-of-function mutations in cancer. Sci Rep 2018;8(1):12846. DOI: 10.1038/s41598-018-31281-0

85. Liu Y., Xu B., Chen F. Recent advances in renal cell carcinoma associated with Xp11.2 translocations/TFE gene fusions. N Am J Med Sci 2012;5(1):43–7.

86. Kinch L., Grishin N.V., Brugarolas J. Succination of Keap1 and activation of Nrf2-dependent antioxidant pathways in FH-deficient papillary renal cell carcinoma type 2. Cancer Cell 2011;20(4):418–20. DOI: 10.1016/j.ccr.2011.10.005

87. Dabbs D.J. Diagnostic immunohistochemistry. 2nd edn. Elsevier Inc., 2006. 848 p.

88. Oda H., Nakatsuru Y., Ishikawa T. Mutations of the p53 gene and p53 protein overexpression are associated with sarcomatoid transformation in renal cell carcinomas. Cancer Res 1995;55(3):658–62.

89. Dolzhansky O.V., Pal'tseva E.M., Bukaeva A.A. et al. The morphological and molecular genetic characteristics of sarcomatoid chrmophobe renal cell carcinoma. Arkhiv patologii = Archive of Pathology 2018;80(4):39–46. (In Russ.). DOI: 10.17116/patol201880439

90. Cserni G., Kovács B.R., Tarján M. et al. Sarcomatoid renal cell carcinoma with foci of chromophobe carcinoma. Pathol Oncol Res 2002;8(2):142–4. DOI: 10.1007/BF03033725

91. Yang Y., Vocke C.D., Ricketts C.J. et al. Genomic and metabolic characterization of a chromophobe renal cell carcinoma cell line model(UOK276). Genes Chromosomes Cancer 2017;56(10): 719–29. DOI: 10.1002/gcc.22476

92. Davis C.F., Ricketts C.J., Wang M. et al. The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell 2014;26(3):319–30. DOI: 10.1016/j.ccr.2014.07.014

93. Носов Д.А. Таргетная терапия при диссеминированном раке почки: успехи и перспективы. Практическая онкология 2010;11(3):171–81.